Every DEF 14A that Dogwood Therapeutics, Inc. (DWTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow DWTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DWTX filings page.
Dogwood Therapeutics, Inc. is asking stockholders to vote at a virtual annual meeting on June 16, 2026. The ballot includes electing seven directors, ratifying Forvis Mazars, LLP as auditor, and advisory Say‑on‑Pay and Say‑on‑Frequency votes.
A key item is a proposal to amend the Certificate of Incorporation to increase authorized common stock from 43,000,000 to 195,000,000 shares and preferred stock from 2,000,000 to 5,000,000 shares, giving the company more flexibility for financing and equity incentives. As of April 26, 2026, 33,401,553 common shares were outstanding. Sealbond Limited beneficially owns 21,822,333 shares, or 65.3%, and Conjoint, Inc. owns 2,842,638 shares, or 8.5%.
The proxy details board structure, committee independence, and executive pay. In 2025, CEO Greg Duncan received total compensation of $3,344,728, while other named executives also received salary, cash bonuses and significant option awards under the company’s 2020 Equity Incentive Plan, which authorizes up to 2,972,787 shares for equity grants.
Dogwood Therapeutics, Inc. has called a virtual special stockholder meeting on March 11, 2026 to vote on two key proposals tied to a recent financing. The main item asks stockholders to approve the exercise of a Common Warrant allowing an investor to purchase up to 4,386,037 shares of common stock at an initial exercise price of $3.28 per share, issued in connection with a January 11, 2026 securities purchase agreement.
The company explains that, together with an unregistered pre-funded warrant for 2,047,089 shares, warrant-related shares represent about 20.05% of its outstanding stock immediately before that agreement, so Nasdaq Listing Rule 5635(d) requires stockholder approval before the Common Warrant can be exercised. If approved, existing holders who are not the investor would be diluted and could see reduced voting power, book value per share and future earnings per share. A second proposal would allow adjournment of the meeting to solicit more proxies if there are not enough votes to pass the warrant proposal.
Dogwood Therapeutics (DWTX) called a virtual special meeting to seek stockholder approval to issue common stock upon conversion of three preferred series tied to recent transactions. Proposal 1 covers Series A, which would convert into 22,691,494 shares; Proposal 2 covers Series A-1 for 2,842,638 shares; Proposal 3 covers Series A-2 for 1,900,572 shares, each effective after approval and Nasdaq’s initial listing application.
The company reports 2,293,162 shares outstanding as of the record date. Following approval and conversion, it expects to issue 27,434,704 shares, for an expected total of 29,727,866 shares outstanding. Post-conversion, beneficial ownership is shown as Sealbond Limited 73.4% and Conjoint, Inc. 9.6%. Certain holders are excluded from voting on Proposals 1 and 3 under Nasdaq rules.
Proposal 4 seeks to increase the equity plan reserve to 2,972,787 shares. Proposal 5 would permit adjournment if needed to secure approvals or Nasdaq’s initial listing application. The meeting is on November 21, 2025 at 10:00 a.m. ET, with an October 14, 2025 record date.